Loading clinical trials...
Loading clinical trials...
Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas
Conditions
Interventions
Rituximab-HDS
Rituximab-CHOP
Locations
16
Italy
Clinica di Ematologia - Nuovo Ospedale Torrette
Ancona, Italy
U.O. Ematologia - Ospedali Riuniti di Bergamo
Bergamo, Italy
Divisione di Ematologia - Ospedale Centrale di Bolzano
Bolzano, Italy
CTMO - Ematologia - Ospedale "R. Binaghi"
Cagliari, Italy
Divisione di Ematologia - Ospedale Ferrarotto
Catania, Italy
S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle
Cuneo, Italy
Start Date
May 1, 2005
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
August 10, 2017
NCT05139017
NCT01804686
NCT05755087
NCT04739813
NCT06785818
NCT06043011
Lead Sponsor
Gruppo Italiano Terapie Innovative nei Linfomi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions